It explains the State Farm agent experience with a flow chart of agent progression through the program, and includes agent testimonials. The brochure does not include any test questions, but the website may be used to find local agents who may be willing to share some tips.
The secondary objectives are safety profile and the response rate. Lapatinib, an oral inhibitor of EGFR and HER2, have been shown to be an effective treatment in HER2/neu overexpressing metastatic breast cancer patient who refractory herceptin, taxane, and anthracycline treatment.
Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors (estimated Kiapp values of 3nM and 13nM, respectively) with a dissociation half-life of â¥300 minutes.